Taysha Gene Therapies, Inc. (TSHA) has disclosed a new risk, in the Innovation / R&D category.
Taysha Gene Therapies, Inc. faces significant business risk as its lead product candidate, TSHA-102, remains in development with no certainty of regulatory approval. The FDA and international regulatory bodies may reject or delay its market entry, which is vital for the company’s success. The extensive and costly approval process poses a substantial challenge, and even with market authorization, there’s no assurance of profitable market acceptance. This singular focus on TSHA-102 amplifies the risk, as any development or commercialization failure could severely impact Taysha’s financial stability and operational outcomes.
The average TSHA stock price target is $6.70, implying 126.35% upside potential.
To learn more about Taysha Gene Therapies, Inc.’s risk factors, click here.
